Directive 1989/342 - Extension of the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Council Directive 89/342/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergensLegal instrument | Directive |
---|---|
Number legal act | Directive 1989/342 |
Original proposal | COM(1987)697 |
CELEX number i | 31989L0342 |
Document | 03-05-1989 |
---|---|
Publication in Official Journal | 25-05-1989; Special edition in Finnish: Chapter 13 Volume 019,Special edition in Swedish: Chapter 13 Volume 019,OJ L 142, 25.5.1989 |
Effect | 17-05-1989; Entry into force Date notif. |
End of validity | 17-12-2001; Repealed by 32001L0083 |
Transposition | 01-01-1992; At the latest See Art 6 |
Notification | 17-05-1989 |
|
Council Directive 89/342/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens
Official Journal L 142 , 25/05/1989 P. 0014 - 0015
Finnish special edition: Chapter 13 Volume 19 P. 0012
Swedish special edition: Chapter 13 Volume 19 P. 0012
COUNCIL DIRECTIVE of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens (89/342/EEC)
THE COUNCIL OF THE EUROPEAN COMMUNITIES,
Hacing regard to the Treaty establishing the European Economic Community, and in particular Article 100a thereof,
Having regard to the proposal from the Commission (1),
In cooperation with the European Parliament (2),
Having regard to the opinion of the Economic and Social Committee (3),
Whereas disparities in the provisions laid down by law, regulation or administrative action by Member States may hinder trade in immunological products within the Community;
Whereas the essential aim of any rules governing the production, distribution or use of medicinal products must be to safeguard public health;
Whereas Directive 65/65/EEC (4), as last amended by Directive 87/21/EEC (5), and Second Directive 75/319/EEC (6), as last amended by Directive 83/570/EEC (7), on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products, although appropriate, are inadequate for immunological medicinal products consisting of vaccines, toxins or serums and allergens;
Whereas, in accordance with Article 5 of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology (8), the Commission is required to submit proposals to harmonize, along the lines of Directive 75/319/EEC, the conditions for authorizing the manufacture and placing on the market of immunological medicinal products before 22 December 1987;
-
16.5. 1989.
Whereas, before an authorization to market an immunological product can be granted, the manufacturer must demonstrate his ability to attain batch-to-batch consistency;
Whereas the Commission should be empowered to adopt any necessary changes in the requirements for the testing of proprietary medicinal products set out in the Annex to Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products (9), as last amended by Directive 87/19/EEC (10), to take account of the special nature of immunological medicinal products in close cooperation with the Committee for the Adaptation to Technical Progress of the Directives on the Removal of Technical Barriers to Trade in the Proprietary Medicinal Products Sector, thus ensuring greater quality, safety and efficacy,
HAS ADOPTED THIS DIRECTIVE:
Article 1
-
1.In derogation from Article 34 of Directive 75/319/EEC, and subject to the provisions of this Directive, Directives 65/65/EEC and 75/319/EEC shall apply to immunological medicinal products for human use consisting of vaccines, toxins or serums and allergen products.
-
2.For the purposes of this Directive, the following definitions shall apply:
-
-'allergen product' shall mean any product which is intended to identify or induce a specific acquired alteration in the immunological response to an allergizing agent,
-
-vaccines, toxins and serums shall have the meaning assigned to them in the Annex to Directive 75/319/EEC.
Article 2
-
1.The...
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.